Prognostic Value of Tumor Volume Assessment on PSMA PET After<sup>177</sup>Lu-PSMA Radioligand Therapy Evaluated by PSMA PET/CT Consensus Statement and RECIP 1.0-Reference-Cited by-同舟云学术

Prognostic Value of Tumor Volume Assessment on PSMA PET After¹⁷⁷Lu-PSMA Radioligand Therapy Evaluated by PSMA PET/CT Consensus Statement and RECIP 1.0

Published:2022-10-27 Issue:4 Volume:64 Page:605-610
ISSN:0161-5505
Container-title:Journal of Nuclear Medicine
language:en
Short-container-title:J Nucl Med

Author:

Kind Felix,Eder Ann-Christin,Jilg Cordula A.,Hartrampf Philipp E.,Meyer Philipp T.,Ruf Juri,Michalski Kerstin

Publisher

Society of Nuclear Medicine

Subject

Radiology, Nuclear Medicine and imaging

Reference28 articles.

1. Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study

2. Results of a Prospective Phase 2 Pilot Trial of 177Lu–PSMA-617 Therapy for Metastatic Castration-Resistant Prostate Cancer Including Imaging Predictors of Treatment Response and Patterns of Progression

3. Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3

4. [ 177 Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study

5. [177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial;Hofman;Lancet.,2021

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Correlation of PSA blood levels with standard uptake value maximum (SUVmax) and total metabolic tumor volume (TMTV) in 18F-PSMA-1007 and 18F-choline PET/CT in patients with biochemically recurrent prostate cancer;Nuclear Medicine Communications;2024-07-30

2. Treatment Response Imaging in Prostate Cancer;PET Clinics;2024-07

3. Should new organ involvement be included in Response Evaluation Criteria in PSMA Imaging?;Annals of Nuclear Medicine;2024-06-16

4. Imaging and therapy in prostate cancer using prostate specific membrane antigen radioligands;British Journal of Radiology;2024-05-11

5. 177Lu-PSMA therapy in metastatic prostate cancer: An updated review of prognostic and predictive biomarkers;Cancer Treatment Reviews;2024-04